Gardasil Death Reports: Are They Causal?

No causal link between Gardasil and death has been established in any clinical trial, post-marketing surveillance review, or epidemiologic study conducted to date. Death reports do exist in the U.S. Vaccine Adverse Event Reporting System (VAERS) and in other passive surveillance databases, but expert review of those cases, including autopsy findings and medical records, has consistently found no pattern pointing to the vaccine as a cause. The distinction between a death that happens after vaccination and a death caused by vaccination is the crux of this question, and it is a distinction that the available evidence draws sharply.

What Pre-Licensure Trials Found

Before Gardasil reached the market, and again before the updated nine-valent version (Gardasil 9) was approved, large Phase III clinical trials tracked tens of thousands of participants for safety. A combined analysis of seven Phase III trials of the nine-valent vaccine reported seven deaths among trial participants. None were considered related to the vaccine.¹ The causes of death in these trials typically included conditions like car accidents, drug overdoses, and pre-existing illnesses. Investigators and independent safety monitoring boards reviewed each case and found no plausible mechanism linking the vaccine to any of the deaths.

This matters because clinical trials are the most controlled environment in which to detect a safety signal. Participants are monitored closely, health records are available in full, and a comparison group receiving a placebo or another vaccine allows researchers to see whether deaths occur more often in the vaccinated group. They did not.

What VAERS Death Reports Mean, and What They Do Not

VAERS is an open system. Anyone can file a report: a doctor, a nurse, a parent, or the person who received the vaccine. Filing a report does not require proof that the vaccine caused the event. The system’s purpose is to detect potential signals that deserve further investigation, not to establish causation. This design is intentional but creates a persistent source of confusion when raw VAERS counts are presented as evidence of harm.

A review of VAERS reports for Gardasil 9 from 2015 through 2024 identified 57 death reports. Neurological terms appeared more often than expected in those reports but without a consistent pattern suggesting a single identifiable cause. The authors concluded that the overall VAERS data supported the established safety of Gardasil 9.² An earlier post-licensure safety review of the nine-valent vaccine found just two verified death reports, and in both cases, nothing in the autopsy reports or death certificates suggested the vaccine played a role.³

Drawing broad conclusions about whether a vaccine causes deaths from VAERS reports alone is not scientifically valid. The system captures temporal associations, where something happened after a vaccine dose, without the methodological controls needed to distinguish coincidence from causation.⁴ Millions of young people receive Gardasil each year. Some of them will, by sheer statistical probability, experience serious health events or die from unrelated causes within days or weeks of a vaccine dose. VAERS captures those events. The question is whether they happen more often than they would have without the vaccine, and that question requires a different kind of study.

Active Surveillance Studies

To move beyond raw report counts, researchers conduct active surveillance studies. These compare the rate of death (or other serious events) in a defined window after vaccination to what would be expected in the same population during a comparable period. One such study used a case-centered design to estimate the risk of death in the 30 days following vaccination among people aged 9 to 26 who died between 2005 and 2011. Deaths from external causes like accidents, homicides, and suicides were excluded from the primary analysis. A team of physicians reviewed available medical records and coroner’s reports to assess each death individually.⁵ The study found no elevated risk of death in the post-vaccination window.

Active surveillance is what separates signal from noise. VAERS can flag a potential concern, but active surveillance answers the question. For Gardasil, both pre-licensure trials and post-licensure active studies converge on the same answer: vaccination does not increase the risk of death.

The Mechanisms That Can Cause Real Harm

Saying “no causal link to death” is not the same as saying “nothing bad ever happens after vaccination.” A handful of well-characterized adverse events are acknowledged by regulators and researchers. The important thing is that these events are rare, usually manageable, and distinct from the vague “Gardasil killed someone” narratives that circulate online.

Syncope and Fall Injuries

Fainting after any injection is common in adolescents and young adults, and Gardasil is no exception. Syncope itself is not dangerous, but falling during a faint can be. A study of adolescent syncope following vaccination and routine blood draws found that about 15% of fainting episodes resulted in some kind of injury, almost all to the face or head. One patient suffered a concussion that took over a month to resolve.⁶ An Australian retrospective study of syncope and seizures after HPV vaccination reported injuries in seven cases, including five head injuries and one vertebral fracture.⁷

Fall-related injuries from post-vaccination syncope are among the rare scenarios where a plausible theoretical pathway from vaccination to death exists, though documented fatal cases are essentially absent from the literature.⁴ This is why vaccination sites typically ask patients to sit or lie down for 15 minutes after receiving an injection. That simple precaution eliminates most of the risk. The U.S. safety review noted that, apart from syncope, no confirmed safety signal emerged from post-licensure monitoring of the quadrivalent HPV vaccine.⁸

Anaphylaxis

Severe allergic reactions can occur after any vaccine. An Australian school-based vaccination program that administered nearly 270,000 HPV vaccine doses identified 7 cases of anaphylaxis, a rate of roughly 2.6 per 100,000 doses. That rate was higher than seen with some other school-delivered vaccines, but every affected patient recovered completely, most within an hour of receiving adrenaline.⁹ Anaphylaxis is dangerous and can theoretically be fatal if untreated, which is why vaccination always takes place in settings where emergency treatment is available. In practice, no confirmed death from Gardasil-related anaphylaxis has been reported in the published literature.

A follow-up study of 25 schoolgirls who reported suspected hypersensitivity reactions after the quadrivalent vaccine found that most did not have true allergies. After skin testing and re-challenge with the vaccine, only 3 of the 25 were classified as having probable hypersensitivity.¹⁰ The gap between suspected and confirmed reactions is a recurring theme in vaccine safety data.

Autoimmune Disease Concerns

Some of the most persistent fears about Gardasil involve autoimmune conditions, including Guillain-Barré syndrome (GBS) and postural orthostatic tachycardia syndrome (POTS). Case reports have described individuals developing POTS after HPV vaccination, and these reports have fueled calls for further research.¹¹ One Danish case series of patients with symptoms of orthostatic intolerance after HPV vaccination called for “urgent” investigation of a possible link.¹²

When researchers moved from case reports to population-level data, the picture looked different. A meta-analysis pooling more than 240,000 vaccinated and 248,000 unvaccinated individuals found no overall correlation between HPV vaccination and autoimmune disorders.¹³ A large cohort study in Denmark and Sweden examined 53 autoimmune and neurological outcomes after quadrivalent HPV vaccination. Of the 23 autoimmune conditions analyzed, 20 showed no significant increase. Three conditions (Behçet’s syndrome, Raynaud’s disease, and type 1 diabetes) had elevated rate ratios, but each met only one of three predefined criteria needed to strengthen the signal, and the timing of cases after vaccination was random rather than clustered, arguing against a causal relationship.¹⁴

The one exception worth noting is GBS. A French cohort study of over 2.25 million girls found a small but statistically significant increase in GBS incidence after HPV vaccination: roughly 1.4 cases per 100,000 person-years among the vaccinated compared to 0.4 among the unvaccinated.¹⁵ GBS is a serious neurological condition, but it is treatable and rarely fatal. Even if the association is real, the absolute risk increase is very small, roughly one additional case per 100,000 vaccinated girls. And the same French study found no increased incidence of any other autoimmune disease examined.

Blood Clot Concerns

Reports of venous thromboembolism (blood clots in the veins) after Gardasil appeared in VAERS and prompted formal investigation. A large Danish study and a separate U.S. study both found no evidence that HPV vaccination increased the risk of blood clots. The Danish study adjusted for oral contraceptive use, which is itself a significant risk factor for clots in young women, and still found no association.¹⁶ The U.S. study examined clot risk in the 7 and 28 days following each dose and found no elevation.¹⁷

A single case report described a 25-year-old woman who developed thrombosis with thrombocytopenia 10 days after Gardasil 9, with features resembling the vaccine-induced thrombotic thrombocytopenia (VITT) syndrome first described after certain COVID-19 vaccines.¹⁸ A single case report cannot establish that a vaccine causes a condition. It flags a possibility for further study. Population-level evidence has not borne out the concern.

How Serious Events Stack Up Overall

A 2025 systematic review and meta-analysis of post-marketing observational data synthesized evidence from 24 studies. Among those included in the pooled analysis, the proportion of all reported adverse events that were classified as serious was about 3.7%. The pooled rate of serious adverse events was roughly 0.04 per 1,000 doses. The authors found no consistent evidence that HPV vaccination increased the risk of any serious adverse outcome.¹⁹ “Serious” in medical reporting means a hospitalization, a disability, or a life-threatening event. It does not mean “caused by the vaccine.” Many serious events in the data are conditions that would have occurred regardless.

How News Coverage Distorts the Picture

One of the most underappreciated factors in the Gardasil death debate is the role of media coverage and internet search behavior in driving adverse event reports themselves. A study analyzing the relationship between news stories, Google searches, and VAERS reporting found that spikes in media coverage about Gardasil side effects were followed by spikes in VAERS reports, suggesting that some reported adverse events were not reactions to the vaccine but reactions to the news.²⁰

The consequences of this feedback loop are not abstract. In Denmark, intensive media coverage of suspected HPV vaccine side effects starting around 2013 contributed to a collapse in vaccination rates, from around 90% down to roughly 50%.²¹ A separate Danish analysis confirmed the timing: the shift in media tone preceded the decline in vaccination uptake.²² Japan experienced an even more dramatic version of this phenomenon. After a cluster of media reports about adverse events, the Japanese government suspended its proactive recommendation of HPV vaccination in 2013, and coverage fell from about 80% to under 1%.²¹

Parents who encountered stories about HPV vaccine harms on social media were roughly nine times more likely to refuse the vaccine than parents who had not encountered such stories.²¹ That nine-fold increase in refusal did not correspond to a nine-fold increase in actual risk. The gap between perceived danger and documented danger widened dramatically when unverified anecdotes replaced peer-reviewed evidence in the public conversation.

What Happened When Japan Stopped Vaccinating

The Japanese experience offers a grim natural experiment in what happens when fear of vaccine side effects overtakes the evidence. Researchers modeled the projected health impact of Japan’s vaccine suspension and found that the benefits of HPV vaccination far outweighed the risks under every scenario tested. One analysis quantified both sides in quality-adjusted life-years: the benefit of preventing cervical cancer, precancerous lesions, and genital warts was roughly 749 quality-adjusted life-years gained per 100,000 people, while the losses from all categories of adverse reactions combined were roughly 12 per 100,000. The risk-to-benefit ratio came out to about 0.016, meaning the vaccine’s benefits exceeded its risks by a factor of more than 60.²³

Japan reinstated its proactive recommendation in 2022, nearly a decade later. The women who missed vaccination during that interval will carry a higher risk of cervical cancer for the rest of their lives. Cervical cancer kills, reliably and measurably. The deaths attributable to Japan’s suspension of HPV vaccination are projected to far exceed any plausible count of vaccine-related harm, a reminder that the most dangerous outcome of the Gardasil death narrative is not any confirmed side effect of the vaccine. It is the cancer that goes unpreventable when people stop getting vaccinated.